Cited by 1,196Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsInflammatory mediators and NSAID effects

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

Open access

in 't Veld, Bas A., Ruitenberg, Annemieke, Hofman, Albert, Launer, Lenore J., van Duijn, Cornelia M., Stijnen, Theo, Breteler, Monique M.B., Stricker, Bruno H.C.·2001·New England Journal of Medicine

DOI 10.1056/nejmoa010178

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Previous studies have suggested that the use of nonsteroidal antiinflammatory drugs (NSAIDs) may help to prevent Alzheimer's disease. The results, however, are inconsistent. METHODS: We studied the association between the use of NSAIDs and Alzheimer's disease and vascular dementia in a prospective, population-based cohort study of 6989 subjects 55 years of age or older who were free of dementia at base line, in 1991. To detect new cases of dementia, follow-up screening was performed in 1993 and 1994 and again in 1997 through 1999. The risk of Alzheimer's disease was estimated in relation to the use of NSAIDs as documented in pharmacy records. We defined four mutually exclusive categories of use: nonuse, short-term use (1 month or less of cumulative use), intermediate-term use (more than 1 but less than 24 months of cumulative use), and long-term use (24 months or more of cumulative use). Adjustments were made by Cox regression analysis for age, sex, education, smoking status, and the use or nonuse of salicylates, histamine Hz-receptor antagonists, antihypertensive agents, and hypoglycemic agents. RESULTS: During an average follow-up period of 6.8 years, dementia developed in 394 subjects, of whom 293 had Alzheimer's disease, 56 vascular dementia, and 45 other types of dementia. The relative risk of Alzheimer's disease was 0.95 (95 percent confidence interval, 0.70 to 1.29) in subjects with short-term use of NSAIDs, 0.83 (95 percent confidence interval, 0.62 to 1.11) in those with intermediate-term use, and 0.20 (95 percent confidence interval, 0.05 to 0.83) in those with long-term use. The risk did not vary according to age. The use of NSAIDs was not associated with a reduction in the risk of vascular dementia. CONCLUSIONS: The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa010178

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop*
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia
Roth, M., Tym, E., Mountjoy, C. Q., Huppert, F. A., Hendrie, H., Verma, S., & Goddard, R. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.149.6.698 · Cited by 2,090
The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Determinants of disease and disability in the elderly: The Rotterdam elderly study
Albert Hofman, D., Grobbee, D. E., de Jong, P. T. V. M., & Ouweland, F. A. V. D. (1991) · European Journal of Epidemiology · doi:10.1007/bf00145007 · Cited by 1,120

Flagged first, then by citations

Show all 44 references

Research works printed but not linked: 4

Brooks W, 1998, Neurobiol Aging, 19, S140
Kukull WA, 1994, Neurology, 44, A237
Cornelius C, 1998, Neurobiol Aging, 19, S28
Time-varying explanatory variables. In: Clayton D, Hills M. Statistical models in epidemiology. Oxford, England: Oxford University Press, 1993:307-18.

Sorted by citations

Items 101–200 of 1,000

The Rotterdam Study: 2012 objectives and design update
Albert Hofman, D., van Duijn, C. M., Franco, O. H., Ikram, M. A., Janssen, H. L. A., Klaver, C. C. W., Kuipers, E. J., Nijsten, T. E. C., Stricker, B. H. C., Tiemeier, H. W., et al. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9610-5 · Cited by 290
Self-citation
Human gut microbiota: the links with dementia development
Alkasir, R., Li, J., Li, X., Jin, M., & Zhu, B. (2016) · Protein & Cell · doi:10.1007/s13238-016-0338-6 · Cited by 289
Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity
Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Ozols, V. V., Fauq, A. H., Golde, T. E., & Koo, E. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303592200 · Cited by 284
Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy
Brown, E. S., Woolston, D. J., Frol, A. B., Bobadilla, L., Khan, D. A., Hanczyc, M., Rush, A. J., Fleckenstein, J., Babcock, E. E., & Cullum, C. M. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.010 · Cited by 280
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
Karran, E. H., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 279
Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases
Kerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H., & Hohlfeld, R. (2003) · Annals of Neurology · doi:10.1002/ana.10446 · Cited by 275
Alzheimer's disease and angiogenesis
Vagnucci, A. H., & Li, W. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12521-4 · Cited by 267
Aspirin triggers antiinflammatory 15-epi-lipoxin A 4 and inhibits thromboxane in a randomized human trial
Chiang, N., Bermudez, E. A., Ridker, P. M., Hurwitz, S., & Serhan, C. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405445101 · Cited by 266
Immune aging, dysmetabolism, and inflammation in neurological diseases
Deleidi, M., JÃ¤ggle, M., & Rubino, G. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00172 · Cited by 260
“The association between nonsteroidal anti-inflammatory drug (NSAID) treatment and lower incidence of AD and PD is still controversial (in t’ Veld et al., 2001; Chen et al., 2003; Wahner et al., 2007; Gao et al., 2011; Rees et al., 2011; Cote et al., 2012; Alzheimer’s Disease Anti-inflammatory…”
Background
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice
Janelsins, M. C., Mastrangelo, M. A., Oddo, S., LaFerla, F. M., Federoff, H. J., & Bowers, W. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-23 · Cited by 260
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
Zotova, E., Nicoll, J. A. R., Kalaria, R. N., Holmes, C., & Boche, D. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt24 · Cited by 269
Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
Gong, Z., Huang, J., Xu, B., Ou, Z., Zhang, L., Lin, X., Ye, X., Kong, X., Long, D., Sun, X., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1450-3 · Cited by 265
“Numerous epidemiological reports supported the finding that anti-inflammatory therapy can reduce the risk for AD by more than 50% [6, 7].”
Local Neuroinflammation and the Progression of Alzheimer's Disease
McGeer, P. L., & McGeer, E. G. (2002) · Journal of NeuroVirology · doi:10.1080/13550280290100969 · Cited by 257
Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Dewachter, I., Walter, J., Klockgether, T., & Van Leuven, F. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-22 · Cited by 309
“long term medication with non-steroidal anti-inflammatory drugs (NSAIDs) appears to decrease the risk, delay the onset and slow the cognitive decline of AD patients [15-17].”
Antioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 255
Etiology of Parkinson’s disease
Schapira, A. H. V. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s10 · Cited by 251
Cyclooxygenase‐2‐positive macrophages infiltrate the Alzheimer’s disease brain and damage the blood–brain barrier
Fiala, M., Liu, Q. N., Sayre, J., Pop, V., Brahmandam, V., Graves, M. C., & Vinters, H. V. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00994.x · Cited by 307
Neuroinflammation in Alzheimer's Disease: Mechanisms, Pathologic Consequences, and Potential for Therapeutic Manipulation
Hensley, K. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1414 · Cited by 258
Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment
Imbimbo (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00019 · Cited by 75
Regulating Factors for Microglial Activation.
Nakamura, Y. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.945 · Cited by 241
Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein
Lyoo, C. H., Ikawa, M., Liow, J., Zoghbi, S. S., Morse, C. L., Pike, V. W., Fujita, M., Innis, R. B., & Kreisl, W. C. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.146027 · Cited by 245
Rosiglitazone rescues memory impairment in Alzheimer’s transgenic mice: Mechanisms involving a reduced amyloid and tau pathology
Escribano, L., Simón, A.-M., Gimeno, E., Cuadrado-Tejedor, M., López de Maturana, R., García-Osta, A., Ricobaraza, A., Pérez-Mediavilla, A., Del Río, J., & Frechilla, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.32 · Cited by 235
Neuroinflammation and Functional Connectivity in Alzheimer's Disease: Interactive Influences on Cognitive Performance
Passamonti, L., Tsvetanov, K. A., Jones, P. S., Bevan-Jones, W. R., Arnold, R., Borchert, R. J., Mak, E., Su, L., O'Brien, J. T., & Rowe, J. B. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.2574-18.2019 · Cited by 220
The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease.
Wilkinson, B. L., & Landreth, G. E. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-30 · Cited by 238
A molecular approach in drug development for Alzheimer’s disease
Agatonović-Kuštrin, S., Kettle, C., & Morton, D. W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.147 · Cited by 240
The Rotterdam Study: 2010 objectives and design update
Hofman, A., Breteler, M. M. B., van Duijn, C. M., Janssen, H. L. A., Krestin, G. P., Kuipers, E. J., Stricker, B. H. C., Tiemeier, H., Uitterlinden, A. G., Vingerling, J. R., et al. (2009) · European Journal of Epidemiology · doi:10.1007/s10654-009-9386-z · Cited by 244
“Commonly used drugs may have a role in this [194].”
BackgroundSelf-citation
Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
Tayeb, H. O., Yang, H. D., Price, B. H., & Tarazi, F. I. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.002 · Cited by 237
Deletion of the Prostaglandin E2EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease
Liang, X., Wang, Q., Hand, T. A., Wu, L., BREYER, R. M., Montine, T. J., & Andreasson, K. I. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3591-05.2005 · Cited by 232
Is Alzheimer’s disease a systemic disease?
Morris, J. K., Honea, R. A., Vidoni, E. D., Swerdlow, R. H., & Burns, J. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.012 · Cited by 219
Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions
Cole, G. M., Lim, G. P., Yang, F., Teter, B., Begum, A. N., Ma, Q., Harris‐White, M. E., & Frautschy, S. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.005 · Cited by 229
The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice
Schütz, B., Reimann, J., Dumitrescu‐Ozimek, L., Kappes‐Horn, K., Landreth, G. E., Schürmann, B., Zimmer, A., & Heneka, M. T. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2038-05.2005 · Cited by 225
Non‐steroidal anti‐inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action
Gasparini, L., Ongini, E., & Wenk, G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02743.x · Cited by 226
Alzheimer's disease and angiogenesis
Agorogiannis, E. I., & Agorogiannis, G. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13000-0 · Cited by 224
Current drug targets for Alzheimer's disease treatment
Lahiri, D. K., Farlow, M. R., Greig, N. H., & Sambamurti, K. (2002) · Drug Development Research · doi:10.1002/ddr.10081 · Cited by 220
“Several recent studies suggest that the use of nonsteroidal anti-inflammatory (NSAIDs) drugs are associated with a reduced risk for developing AD [In t’ Veld et al., 2001].”
Background
Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia
van Oijen, M., Witteman, J. C., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2005) · Stroke · doi:10.1161/01.str.0000189721.31432.26 · Cited by 222
Self-citation
Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity
Kotilinek, L., Westerman, M. A., Wang, Q., Panizzon, K. L., Lim, G. P., Simonyi, Á., Lesné, S., Falinska, A. M., Younkin, L. H., Younkin, S. G., et al. (2008) · Brain · doi:10.1093/brain/awn008 · Cited by 223
Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains
Shi, J.-Q., Shen, W., Chen, J., Wang, B.-R., Zhong, L.-L., Zhu, Y.-W., Zhu, H.-Q., Zhang, Q.-Q., Zhang, Y.-D., & Xu, J. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.053 · Cited by 219
Emerging roles of PGE2 receptors in models of neurological disease
Andreasson, K. I. (2009) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2009.04.003 · Cited by 225
Mitochondrial Ca2+ Overload Underlies Aβ Oligomers Neurotoxicity Providing an Unexpected Mechanism of Neuroprotection by NSAIDs
Sanz‐Blasco, S., Valero, R. A., Rodríguez‐Crespo, I., Villalobos, C., & Núñez, L. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002718 · Cited by 221
Microglial immunophenotype in dementia with Alzheimer’s pathology
CFAS, M., Minett, T., Classey, J., Matthews, F. E., Fahrenhold, M., Taga, M., Brayne, C., Ince, P. G., Nicoll, J. A. R., & Boche, D. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0601-z · Cited by 219
“Epidemiological retrospective studies also support the “inflammation hypothesis” of Alzheimer’s disease with evidence that non-steroidal anti-inflammatory drugs may be protective against the development of Alzheimer’s disease [8–10].”
Result
Peripheral immune system in aging and Alzheimer’s disease
Cao, W., & Zheng, H. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0284-2 · Cited by 214
The Neurobiology of Autism
Bauman, M. L. (2006) · Johns Hopkins University Press eBooks · doi:10.1353/book.3225 · Cited by 215
Therapeutic B-cell depletion reverses progression of Alzheimer’s disease
Kim, K., Wang, X., Ragonnaud, E., Bodogai, M., Illouz, T., DeLuca, M., McDevitt, R. A., Gusev, F., Okun, E., Rogaev, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22479-4 · Cited by 206
Intermittent fasting attenuates lipopolysaccharide-induced neuroinflammation and memory impairment.
Vasconcelos, A. R., Yshii, L. M., Viel, T. A., Buck, H. S., Mattson, M. P., Scavone, C., & Kawamoto, E. M. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-85 · Cited by 210
Wnt signaling in neuroprotection and stem cell differentiation
Toledo, E. M., Colombres, M., & Inestrosa, N. C. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.08.001 · Cited by 214
Transcriptional and epigenetic decoding of the microglial aging process
Li, X., Li, Y., Jin, Y., Zhang, Y., Wu, J., Xu, Z., Huang, Y., Cai, L., Gao, S., Liu, T., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00479-x · Cited by 234
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Szekely, C. A., Breitner, J. C. S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., & Zandi, P. P. (2008) · Neurology · doi:10.1212/01.wnl.0000284596.95156.48 · Cited by 204
In vivo evidence for the contribution of peripheral circulating inflammatory exosomes to neuroinflammation
Li, J. J., Wang, B., Kodali, M. C., Chen, C., Kim, E., Patters, B. J., Lan, L.-B., Kumar, S., Wang, X., Yue, J., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1038-8 · Cited by 210
The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease
Aisen, P. S. S. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00133-3 · Cited by 203
The Role of Inflammation in the Pathogenesis of Delirium and Dementia in Older Adults: A Review
Simone, M. J., & Tan, Z. S. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00173.x · Cited by 204
CNS Infiltration of Peripheral Immune Cells: D-Day for Neurodegenerative Disease?
Rezai-Zadeh, K. P., Gate, D., & Town, T. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9166-2 · Cited by 202
Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti‐inflammatory drugs
Townsend, K. P., & Praticò, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3620rev · Cited by 194
Brain Uptake of Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen, Flurbiprofen, and Indomethacin
Parepally, J. M. R., Mandula, H., & Smith, Q. R. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9905-5 · Cited by 196
Cognitive function in dialysis patients
Pereira, A. A., Weiner, D. E., Scott, T. M., & Sarnak, M. J. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.10.024 · Cited by 191
Alzheimer’s Disease, Oligomers, and Inflammation
Forloni, G., & Balducci, C. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170819 · Cited by 205
Factors that influence adult neurogenesis as potential therapy
Shohayeb, B., Diab, M., Ahmed, M., & Ng, D. C. H. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0109-9 · Cited by 206
Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer’s Disease
Czapski, G. A., & Strosznajder, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111677 · Cited by 198
Young microglia restore amyloid plaque clearance of aged microglia
Daria, A., Colombo, A., Llovera, G., Hampel, H., Willem, M., Liesz, A., Haass, C., & Tahirovic, S. (2017) · The EMBO Journal · doi:10.15252/embj.201694591 · Cited by 174
“…(NSAIDs) suggested that inhibiting the immune system may also be of benefit in reducing the disease incidence or slowing down AD progression (Stewart et al , 1997; Anthony et al , 2000; in t’ Veld et al , 2001; Zandi et al , 2002; Monsonego & Weiner, 2003; Heneka et al , 2005; Yip et al , 2005).”
Association between high‐density lipoprotein and cognitive impairment in the oldest old
van Exel, E. R., de Craen, A. J. M., Gussekloo, J., Houx, P. J., Wiel, A. B. D., Macfarlane, P. W., Blauw, G. J., & Westendorp, R. G. J. (2002) · Annals of Neurology · doi:10.1002/ana.10220 · Cited by 189
Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity
Arendt, T. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.007 · Cited by 189
Angiotensin-Converting Enzyme Converts Amyloid β-Protein 1–42 (Aβ 1–42 ) to Aβ 1–40 , and Its Inhibition Enhances Brain Aβ Deposition
Zou, K., Yamaguchi, H., Akatsu, H., Sakamoto, T., Ko, M.-H., Mizoguchi, K., Gong, J.-S., Yu, W., Yamamoto, T., Kosaka, K., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1549-07.2007 · Cited by 193
Nutritional determinants of cognitive aging and dementia
Morris, M. C. (2011) · Proceedings of The Nutrition Society · doi:10.1017/s0029665111003296 · Cited by 196
NF-κB as a therapeutic target in neurodegenerative diseases
Camandola, S., & Mattson, M. P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.123 · Cited by 184
Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
Dionisio-Santos, D. A., Olschowka, J. A., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1453-0 · Cited by 184
Neuroinflammatory perspectives on the two faces of Alzheimer?s disease
Eikelenboom, P., & van Gool, W. A. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0055-1 · Cited by 183
Bioactive Compounds from Macroalgae in the New Millennium: Implications for Neurodegenerative Diseases
Barbosa, M., Valentão, P., & Andrade, P. (2014) · Marine Drugs · doi:10.3390/md12094934 · Cited by 181
Atypical inflammation in the central nervous system in prion disease
Perry, V. H., Cunningham, C. M., & Boche, D. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200206000-00020 · Cited by 183
Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort
Breitner, J. C. S., Haneuse, S., Walker, R. L., Dublin, S., Crane, P. K., Gray, S. L., & Larson, E. B. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a18691 · Cited by 175
Sulindac Sulfide Is a Noncompetitive γ-Secretase Inhibitor That Preferentially Reduces Aβ42 Generation
Takahashi, Y., Hayashi, I., Tominari, Y., Rikimaru, K., Morohashi, Y., Kan, T., Natsugari, H., Fukuyama, T., Tomita, T., & Iwatsubo, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301619200 · Cited by 177
Minocycline inhibits LPS-induced retinal microglia activation
Wang, A., Yu, A. C., Lau, L. T., LEE, C., WU, L., ZHU, X., & Tso, M. O. M. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.04.018 · Cited by 178
“A prospective population-based cohort study of about 7000 individuals revealed that the relative risk of Alzheimer's disease decreases with prolonged use (more than 2 years) of nonsteroidal anti-inflammatory drugs (NSAIDs) (In't Veld et al., 2001).”
Background
Microglia as a Potential Bridge between the Amyloid β‐Peptide and Tau
Kitazawa, M., Yamasaki, T. R., & LaFerla, F. M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.006 · Cited by 187
The amyloidogenic potential and behavioral correlates of stress
Catania, C., Sotiropoulos, I., Silva, R., Onofri, C., Breen, K. C., Sousa, N., & Almeida, O. F. X. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002101 · Cited by 177
NETosis in Alzheimer’s Disease
Pietronigro, E. C., Bianca, V. D., Zenaro, E., & Constantin, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00211 · Cited by 179
The Role of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) in Alzheimer’s Disease
Jiang, Q., Heneka, M. T., & Landreth, G. E. (2008) · CNS Drugs · doi:10.2165/00023210-200822010-00001 · Cited by 176
“[23] Alzheimer’s disease.”
‘Too much good news’ – are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?
Zahs, K. R., & Ashe, K. H. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.05.004 · Cited by 179
NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies
Zhang, C., Wang, Y., Wang, D., Zhang, J., & Zhang, F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00083 · Cited by 184
The Role of Clusterin in Alzheimer’s Disease: Pathways, Pathogenesis, and Therapy
Yu, J.-T., & Tan, L. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8237-1 · Cited by 174
Estrogens, inflammation and cognition
Au, A., Feher, A., McPhee, L., Jessa, A., Oh, S. J., & Einstein, G. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.01.002 · Cited by 190
Periodontitis and Alzheimer’s Disease: A Possible Comorbidity between Oral Chronic Inflammatory Condition and Neuroinflammation
Teixeira, F. B., Saito, M. T., MATHEUS, F. C., Prediger, R. D., Yamada, E. S., Maia, C. D. S. F., & Lima, R. R. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00327 · Cited by 189
A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease
Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172
In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile
Agdeppa, E. D., Kepe, V., Petri, A., Satyamurthy, N., Liu, J., Huang, S. C., Small, G. W., Cole, G. M., & Barrio, J. R. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00907-7 · Cited by 172
Lack of Genetic Associations of PPAR-γ and PGC-1α with Alzheimer's Disease and Parkinson's Disease with Dementia
Shibata, N., Motoi, Y., Tomiyama, H., Ohnuma, T., Kuerban, B., Tomson, K., Komatsu, M., Shimazaki, H., Hattori, N., & Arai, H. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000351419 · Cited by 171
Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology
Hoozemans, J. J. M., Veerhuis, R., Rozemüller, A. J. M., & Eikelenboom, P. (2005) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.001 · Cited by 171
Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide
Espuny-Camacho, I., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D. I., & Strooper, B. D. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3987-04.2004 · Cited by 171
Neuroprotective Effects of Meloxicam and Selegiline in Scopolamine-Induced Cognitive Impairment and Oxidative Stress
Puchchakayala, G. R., Akina, S., & Thati, M. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/974013 · Cited by 171
Alzheimer's Disease and Peripheral Infections: The Possible Contribution from Periodontal Infections, Model and Hypothesis
Kamer, A. R., Dasanayake, A. P., Craig, R. G., Głodzik-Sobańska, L., Bry, M., & de Leon, M. J. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13408 · Cited by 169
Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection
Jiang, J.-X., & Dingledine, R. (2013) · TIPS - Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.05.003 · Cited by 167
The roles of amyloid precursor protein (APP) in neurogenesis
Zhou, Z., Chan, C. H.-S., Ma, Q., Xu, X., Xiao, Z., & Tan, E. (2011) · Cell Adhesion & Migration · doi:10.4161/cam.5.4.16986 · Cited by 179
Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models
Johansson, J. U., Woodling, N. S., Wang, Q., Panchal, M., Liang, X., Trueba-Saiz, A., Brown, H. D., Mhatre, S. D., Loui, T., & Andreasson, K. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77487 · Cited by 161
“Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage.”
Genetic deletion or pharmacological inhibition of cyclooxygenase‐1 attenuate lipopolysaccharide‐ induced inflammatory response and brain injury
Choi, S., Langenbach, R. I., & Bosetti, F. (2007) · The FASEB Journal · doi:10.1096/fj.07-9411com · Cited by 159
Prostaglandin D2 mediates neuronal protection via the DP1 receptor
Liang, X., Wu, L., Hand, T. A., & Andreasson, K. I. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02870.x · Cited by 159
Increased production of inflammatory cytokines in mild cognitive impairment
Magaki, S., Mueller, C., DICKSON, C., & Kirsch, W. M. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.09.015 · Cited by 157
Synthesis, Characterization, and Metal Coordinating Ability of Multifunctional Carbohydrate-Containing Compounds for Alzheimer's Therapy
Storr, T., Merkel, M., Song-Zhao, G. X., Scott, L. E., Green, D. E., Bowen, M. L., Thompson, K. H., Patrick, B. O., Schugar, H. J., & Orvig, C. (2007) · Journal of the American Chemical Society · doi:10.1021/ja068965r · Cited by 156
Dementia Prevention: Methodological Explanations for Inconsistent Results
Coley, N., Andrieu, S., Gardette, V., Guyonnet, S., Sanz, C., Vellas, B. J., & Grand, A. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn010 · Cited by 162
Neuroprotective effect of nicotine on dopaminergic neurons by anti‐inflammatory action
Park, H., Lee, P., Ahn, Y.-W., Choi, Y.-J., Lee, G., Lee, D.-Y., Chung, E., & Jin, B. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05636.x · Cited by 145
Non-familial Alzheimer's disease is mainly due to genetic factors
Ashford, J. W., & Mortimer, J. A. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4307 · Cited by 151
“Also, there have been studies of NSAID use among arthritis patients that have indicated that these drugs reduce the risk of AD [ 61 ]; although this finding suggests a way to counter genetic risk associated with AD [63], rather than speaking against genetic causation.”
Assessment of Neuroinflammation and Microglial Activation in Alzheimer’s Disease with Radiolabelled PK11195 and Single Photon Emission Computed Tomography
Versijpt, J. J., Dumont, F., van Laere, K. J., Decoo, D., Santens, P., Audenaert, K., Achten, E., Slegers, G., Dierckx, R., & Korf, J. (2003) · European Neurology · doi:10.1159/000070857 · Cited by 152
“Epidemiologically, almost 20 retrospective studies have already shown the protective effect of nonsteroidal anti-inflammatory drugs (NSAIDs) in populations with a long history of NSAID consumption which would reduce the AD prevalence by 50p and delay its onset by 5–7 years [ , ,”
Background
The role of pro-inflammatory S100A9 in Alzheimer’s disease amyloid-neuroinflammatory cascade
Wang, C., Klechikov, A. G., Gharibyan, A. L., Wärmländer, S. K. T. S., Jarvet, J., Zhao, L., Jia, X., Shankar, S. K., Olofsson, A., Brännström, T., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1208-4 · Cited by 154
Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis
Carter, C. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.07.007 · Cited by 149
Peripheral Inflammatory Cytokines as Biomarkers in Alzheimer’s Disease and Mild Cognitive Impairment
Guerreiro, R. J., Santana, I. J., Brás, J., Santiago, B., Paiva, A. A., & Oliveira, C. R. (2007) · Neurodegenerative Diseases · doi:10.1159/000107700 · Cited by 150

Authors: in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C.
Affiliations: Erasmus MC (NL)
National Institutes of Health (US)
ORCID: Launer, Lenore J.
Stijnen, Theo
Breteler, Monique M.B.
Stricker, Bruno H.C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-11-22
Volume: 345
Issue: 21
Pages: 1515-1521
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa010178
OpenAlex: W2083556882
Semantic Scholar: 29c01ac52ec50618ec7b3b87ca55b707ca397434
Cited by: 1,196
References: 44
Citations by year: 2026: 13 · 2025: 14 · 2024: 18 · 2023: 23 · 2022: 26 · 2021: 33 · 2020: 23 · 2019: 40 · 2018: 38 · 2017: 28 · 2016: 40 · 2015: 49 · 2014: 49 · 2013: 39 · 2012: 50
FWCI: 52.61
Type: journal article
Language: en
Open access: green
pure.eur.nl
Licence: other-oa
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
RePub (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords: nonsteroidal anti-inflammatory drugs, Alzheimer's disease, vascular dementia, dementia risk, long-term NSAID use, older adults
MeSH terms: Aged, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prospective Studies, Risk, Salicylates, Dementia, Vascular, Cohort Studies, Proportional Hazards Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks